FMK

Overview

FMK is a potent, highly specific and irreversible ribosomal s6 kinase (RSK) inhibitor that covalently modifies the C-terminal kinase domain of RSK. Its IC50 value is 15 nM. It could prevent the activation of the N-terminal kinase domain of RSK by the C-terminal kinase domain, but does not affect the activity of the N-terminal domain. It binds in the CTKD ATP-binding site and inhibits RSK autophosphorylation at Ser386. It induces significant apoptosis in human FGFR3-expressing, t(4;14)-positive multiple myeloma cells. It is used to determine the role of RSK as a direct regulator of NHE1 phosphorylation and sarcolemmal NHE activity in this cell type, in response to 1-adrenergic stimulation.

Application

Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Cancer | Ribosomal S6 Kinase (RSK)

Product Information

• Catalog No.: B0084-455721
• CAS No.: 821794-92-7
• Molecular Formula: C18H19FN4O2
• Molecular Weight: 342.37
• Purity: >98%
• Storage: -20°C Freezer
• Solubility: 10 mM in DMSO

Source

Original product source